Kineta could receive more than $359 million as a result of the deal.
Seattle biotech Kineta will partner with big biotech company Genentech to make and sell a drug used to treat chronic pain, in a deal that could be worth more than $359 million for the Seattle company.
Kineta announced Monday it made a deal with San Francisco-based Genentech to develop Kineta’s existing target therapy into a medicine that treats nerve pain.
“There is a tremendous unmet patient need to develop more effective, safer and nonaddictive therapies for the many people who suffer from chronic pain,” Kineta CEO Shawn Iadonato said in a statement Monday.
The Seattle company will be eligible to receive up to $359 million as part of the deal, in addition to an undisclosed upfront payment. It could also receive royalties on eventual sales of products that result from the deal.
Most Read Business Stories
- Boeing, pursuing its 797 concept, woos a key Airbus customer and stirs industry debate
- Airbus CEO Enders says challenge to Boeing will grow even stronger
- MGM sues Vegas mass-shooting victims in hopes of limiting liability
- Farnborough Air Show: GE still unconvinced about demand for 797
- Bitter legal fight roils Harley Marine Services, a big player on Seattle waterfront